GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
GRI Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.45+0.07 (+5.07%)
Close on Oct 19, 2026
- Market cap
- $2.62M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -548.0% | -238.2% | |
| Return on assets | – | – | -166.0% | |
| Current ratio | – | 0.30 | 3.25 | |
| Debt to equity | – | -0.01 | – | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
GRI Bio generated $37.18M from operations and spent $14.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$37.18M
Used
$14.00K
Capital expenditure$14.00K100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$11.96M
- Cash generatingOperating cash flow above zero-$10.19M
- Return on assets improvedROA up on the prior year-277.6% → -208.3%
- Earnings backed by cashOperating cash flow above net income-$10.19M vs -$11.96M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.43 → 3.25
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –